

## Adherium announces non-renounceable rights issue

**11 December 2019: Adherium Limited** (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease is pleased to announce the launch of a \$5.4m capital raise ("**Offer**"). The Offer, with a minimum subscription of \$2.5m, is a 1 for 1 non-renounceable pro rata offer of approximately 180 million New Shares to all eligible shareholders registered with an address in Australia or New Zealand as at the Record Date (namely 7.00pm Monday 16 December), with the Company reserving the right (in accordance with ASX Listing Rule 7.2 exception 3) to place any shortfall.

All New Shares issued will rank equally with existing ordinary shares. The Offer is expected to close on Friday, 10 January 2020, with new shares allotted Friday, 17 January 2020.

### Use of proceeds

The funds from the Offer will be used by the Company towards advancing the Company's plans to develop features in its product range to gain reimbursement, extend the portfolio of products from asthma into COPD, and for working capital purposes. The proposed use of funds based on a fully subscribed offer is outlined in further detail below:

Next generation Hailie® sensors incorporating physiological measures and extended portfolio for COPD	\$2,730,000
Global market access and reimbursement initiatives	\$412,000
Extension of UK and US sales channels	\$1,100,00
Working capital and offer costs	\$1,150,000
<b>Total use of funds</b>	<b>\$5,392,000</b>

### Anticipated Timetable

Rights Issue announced	11 December 2019
Letter sent to option holders advising they cannot participate in the Rights Issue without first exercising their options.	11 December 2019
'ex' date	13 December 2019
Record date to determine entitlements under the Rights Issue Offer	16 December 2019
Rights Issue document dispatched to shareholders and Rights Issue Offer opens	19 December 2019
Rights Issue Offer closes	10 January 2020
Rights Issue securities quoted on a deferred settlement basis	13 January 2020
Allotment of New Shares issued under the Rights Issue Offer. Deferred settlement trading ends.	17 January 2020



The timetable is indicative only and the Company reserves the right to amend the dates at its discretion and without notice, subject to the ASX Listing Rules and the *Corporations Act 2001* (Cth) (**Corporations Act**).

The board of directors of Adherium Limited has authorised this announcement to be given to the ASX.

**About Adherium (ASX: ADR):** Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices, with more than 170,000 sold globally. The company develops, manufactures and supplies a broad range of connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organisations. Adherium's Hailie® solution is designed to help patients achieve better adherence and provide visibility to parents and caregivers. It does this by tracking medication use and reminding the user with helpful nudges when it's time to take doses, and by providing access to usage history to better understand patterns in their asthma and COPD. These tools ultimately enable people who live with asthma or COPD to more easily manage their condition alongside their physician. Learn more at [adherium.com](https://adherium.com).

**For more information, please contact**

**Corporate enquiries**

Peter Stratford

Adherium Limited

CEO

[investors@adherium.com](mailto:investors@adherium.com)